Trending Topics

and/or

104 Trending Topics found

Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in JAMA Oncology.

  • Thursday, July 18, 2019

Surviving with Pride: Obstacles and Opportunities for LGBTQ+ Cancer Survivors

Today is the fourth anniversary of same-sex marriage being legalized in the United States. Today also marks the start of WorldPride, which celebrates the progress made toward LGBTQ+ equality while underscoring changes still needed.

  • Thursday, June 27, 2019

MSK-ACCESS Receives New York State Approval for New Molecular Assay

Memorial Sloan Kettering Cancer Center (MSK) today announced that the New York State Department of Health has issued approval for a new molecular assay, Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS).  MSK-ACCESS was developed within the Marie-Josee and Henry R. Kravis Center for Molecular Oncology (CMO) and the test has been clinically validated and implemented by members of MSK’s Molecular Diagnostics Service.

  • Tuesday, June 11, 2019

MSK Research and Experts at the 2019 ASCO Annual Meeting: Caring for Every Patient, Learning from Every Patient

More than 30,000 oncology professionals from around the world will gather in Chicago from May 31 to June 4 for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. For more information and to set up interviews, email mcnamarn@mskcc.org. Follow the meeting live on Twitter using the hashtag #ASCO19 and follow MSK on Twitter at @sloan_kettering.

  • Wednesday, May 29, 2019

World-Renowned Molecular Biologist Maria Jasin Wins the Shaw Prize in Life Science and Medicine

Maria Jasin, PhD, a molecular biologist at the Sloan Kettering Institute, was named a recipient of the Shaw Prize in Life Science and Medicine. Dr. Jasin was recognized for her contributions to research showing that localized double-strand breaks in DNA stimulate recombination in mammalian cells.

  • Tuesday, May 21, 2019

High-Impact Science and Clinical Trial Results from MSK Experts Highlighted at the AACR 2019 Annual Meeting

Thousands of oncology experts from around the world will gather in Atlanta from March 29 – April 3 for the American Association for Cancer Research (AACR) Annual Meeting 2019. Memorial Sloan Kettering experts are involved in notable research presented at the meeting and are available to comment on topics including immunotherapy, precision medicine and targeted treatments, genomics, cancer interception and prevention, clinical trial design, cancer health disparities, and more. For more information and to set up interviews or access photos and video, contact mcnamarn@mskcc.org and odonnele@mskcc.org.

  • Thursday, March 28, 2019

MSK Researchers Identify a New Method to “Genetically Cloak” Cancer-Fighting Immune Cells

Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD, has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells, from self-destructing. During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness. The use of “genetic cloaking” prevents immune cell apoptosis, enhancing the effectiveness of cellular immunotherapies for liquid and solid cancers in mouse models. This new technique is also effective in protecting human cancer-fighting immune cells. These findings lay the groundwork for a potentially universal gene-engineering strategy to safely increase the potency of cellular immunotherapies for a broad range of cancers.

  • Tuesday, January 29, 2019

Analyzing Spinal Fluid Could Guide Brain Tumor Diagnosis and Treatment

Doctors have had limited success developing targeted therapies for the treatment of glioblastoma and lower-grade glioma, the most common primary brain cancers in adults. Targeted therapy requires matching drugs to the genetic profile of a tumor, which can substantially change throughout the course of the disease. Keeping track of these changes is particularly challenging in people with brain tumors because collecting tumor DNA requires brain surgery. But experts from MSK have shown that utilizing the minimally invasive procedure commonly called a spinal tap may help doctors better understand a tumor’s changing genetic makeup, offering clues into such traits as tumor aggressiveness.

  • Wednesday, January 23, 2019

Targeted Therapy, Sorafenib, Shows Promise as First-Line Treatment for Previously Untreatable Rare Tumors

In patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib (Nexavar®) significantly improved progression-free survival (PFS) and induced durable responses. This study defined an active therapy for desmoid tumors that appears effective in slowing disease progression.

  • Wednesday, December 19, 2018

Memorial Sloan Kettering Breast Cancer Experts to Gather at Annual San Antonio Breast Cancer Symposium

Experts from all specialties of breast cancer treatment will attend the 2018 San Antonio Breast Cancer Symposium from December 4 through 8. It is the largest annual meeting devoted solely to the latest in breast cancer advances. The meeting will highlight emerging research and also tackle some of the larger issues facing people with breast cancer and the doctors who treat them.

  • Monday, December 3, 2018